Analyst Price Targets — VVOS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 1:45 pm | — | H.C. Wainwright | $2.50 | $1.01 | TheFly | Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright |
| April 17, 2026 12:26 pm | — | Industrial Alliance Securities | $1.75 | $1.00 | TheFly | Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global |
| May 20, 2025 11:03 am | Scott Henry | Industrial Alliance Securities | $2.25 | $2.15 | TheFly | Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners |
Latest News for VVOS
LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered…
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital…
LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced the…
LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced that new OSA patient referrals flowing into its…
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VVOS.
U.S. House Trading
No House trades found for VVOS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.